Hematology · Pediatrics · 3 h ago
Mitochondrial transfer linked to macrophage immunosuppression in pediatric AML
A laboratory study incorporating pediatric acute myeloid leukemia patient findings links mitochondrial transfer from leukemic cells to macrophage immunosuppression. Co-culture experiments implicated tunneling nanotubes in metabolic reprogramming associated with chemoresistance and reduced immune-mediated killing; the supplied abstract does not report sample sizes.
- AML cells transferred mitochondria to macrophages through tunneling nanotubes.
- Macrophage reprogramming required direct contact and favored oxidative phosphorylation.
- Reprogrammed macrophages impaired immune killing and conferred chemoresistance.
- Clinical benefit from targeting this mechanism remains unestablished.
A study published in Leukemia investigated how macrophages contribute to immune suppression in pediatric acute myeloid leukemia (AML). Researchers examined the AML microenvironment in pediatric patients and used co-culture experiments to study interactions between leukemic cells and macrophages. The supplied abstract does not report patient numbers or quantitative effect estimates.
Immunosuppressive macrophages dominated the AML microenvironment and supported growth of RUNX1::RUNX1T1 and KMT2A-rearranged leukemic blasts. In co-culture, AML cells shifted naïve and pro-inflammatory macrophages toward an anti-inflammatory state, suppressing NF-κB and other inflammatory pathways. This shift required direct cell contact and involved transfer of AML mitochondria to macrophages through tunneling nanotubes, associated with metabolic rewiring toward oxidative phosphorylation.
Reprogrammed macrophages showed impaired phagocytosis, conferred chemoresistance, and reduced T-cell– and bispecific antibody–mediated killing. These findings identify AML–macrophage interactions as a potential therapeutic target to improve immune-mediated treatment responses. However, the reported mechanistic experiments do not establish that blocking mitochondrial transfer improves clinical outcomes, and the supplied material provides no clinical intervention results.
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Leukemia: Mitochondria transfer via tunneling nanotubes drives macrophage immunosuppression and metabolic reprogramming in pediatric AML ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.